Novartis | pharmaphorum

Thursday 18 December 2025

Novartis

News

Lab-in-a-loop specialist Relation attracts Novartis alliance

Lab-in-a-loop specialist Relation attracts Novartis alliance

UK-based AI and multi-omics company Relation Therapeutics will seek out targets for allergic diseases on behalf of Novartis in a $1.7bn-plus alliance.

News

Boy in wheelchair, only lower half of his body visible

Novartis' SMA gene therapy cleared for wider use in US

A new FDA approval means Novartis now has a gene therapy option for almost everyone with spinal muscular atrophy (SMA), regardless of their age.

News

malaria in red blood cell

Novartis says novel drug could counter malaria resistance

Novartis has reported what looks like another big step forward in the treatment of malaria, as a drug with a novel mechanism hits the mark in phase 3.

News

Novartis chief executive Vas Narasimhan

Novartis' new drugs outweigh Entresto decline in Q3

Now feeling the impact of generic competition on its top product Entresto in the US, Novartis is still looking for pipeline-building deals, says CEO.

News

Novartis makes $12bn wager on RNA drugs with Avidity buy

Novartis makes $12bn wager on RNA drugs with Avidity buy

Novartis is poised to make one of its largest takeover deals in its history after agreeing to buy RNA specialist Avidity Biosciences for $12bn.

News

ESMO: Lilly reveals scale of survival win with Verzenio

ESMO: Lilly reveals scale of survival win with Verzenio

Eli Lilly has revealed long-term follow-up data with adjuvant Verzenio in early breast cancer, including a 15.8% improvement in survival.